DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluation of butorphanol and cyproheptadine for prevention of cisplatin-induced vomiting in dogs.

Author(s): Moore AS, Rand WM, Berg J, L'Heureux DA, Dennis RA

Affiliation(s): School of Veterinary Medicine, Tufts University, North Grafton, MA 01536.

Publication date & source: 1994-08-01, J Am Vet Med Assoc., 205(3):441-3.

Publication type: Clinical Trial; Comparative Study ; Randomized Controlled Trial

Cisplatin was administered at a dosage of 50 mg/m2 of body surface to 69 dogs with various neoplasms. Dogs were randomly assigned to receive antiemetics according to 1 of the following 5 protocols: group 1, no antiemetic (control, n = 45 treatments); group 2, 0.4 mg of butorphanol/kg of body weight (n = 52 treatments); group 3, 0.2 mg of butorphanol/kg (n = 19 treatments); group 4, 2 mg of cyproheptadine/kg (n = 48 treatments); and group 5, 1 mg of cyproheptadine/kg (n = 10 treatments). Randomization was performed for each dog prior to each treatment. Butorphanol was administered IM immediately after completion of cisplatin infusion. Cyproheptadine was given orally 12 to 14 hours before and again immediately before cisplatin administration. The proportion of dogs that vomited in group 1 was 40 of 45 (89%). Butorphanol at a dosage of 0.4 mg/kg proved highly effective in preventing cisplatin-induced vomiting, reducing the proportion of dogs that vomited (10/52, 19%) compared with the control group.

Page last updated: 2007-05-02

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017